Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
- Conditions
- Advanced Renal Cell Carcinoma (aRCC)
- Registration Number
- NCT06345183
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 327
Inclusion Criteria:<br><br> 1. Age 18 years and older with diagnosis of Advanced Renal Cell Carcinoma (aRCC) with<br> predominantly clear-cell histology<br><br> 2. Received any of the following therapies in the first-line setting:<br><br> 1. Nivolumab + Ipilimumab between 8/1/2021 and 6 months prior to data collection<br><br> 2. Pembrolizumab + Lenvatinib between 8/1/2021and 6 months prior to data<br> collection<br><br> 3. Participant had at least 6 months of follow-up from initiation of index treatment<br> (patients who deceased prior to 6 months since index treatment initiation would<br> still be eligible)<br><br>Exclusion Criteria:<br><br> 1. Receipt of any immunotherapy or tyrosine kinase inhibitor (TKI) therapy as part of a<br> Randomized Controlled Trial (RCT)<br><br> 2. Participant received any systemic therapy for Advanced Renal Cell Carcinoma (aRCC)<br> prior to index therapy, including neoadjuvant or adjuvant therapy<br><br> 3. Any active malignancy in the 3 years prior to initiation of 1L therapy for aRCC,<br> except for locally curable cancers that have been cured, such as basal or squamous<br> cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, or<br> breast cancer, or localized prostate cancer with a Gleason score =3+4 that has been<br> treated more than 12 months prior to full study screening and considered to have a<br> very low risk of recurrence.
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method